CN110361485A - Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood - Google Patents
Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood Download PDFInfo
- Publication number
- CN110361485A CN110361485A CN201910671617.9A CN201910671617A CN110361485A CN 110361485 A CN110361485 A CN 110361485A CN 201910671617 A CN201910671617 A CN 201910671617A CN 110361485 A CN110361485 A CN 110361485A
- Authority
- CN
- China
- Prior art keywords
- content
- oxcarbazepine
- concentration
- sample
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/16—Injection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
Abstract
The present invention relates to medical detection fields, more particularly to Oxcarbazepine and its metabolite Therapeutic Drug Monitoring kit in a kind of blood based on multidimensional on-line solid phase extraction liquid-phase chromatographic analysis technological development, the method that accurate quantitative analysis detection is more specifically carried out to Oxcarbazepine in blood and its metabolite drug concentration using on-line solid phase extraction and multidimensional liquid-phase chromatographic analysis technology.Kit includes calibration object reagent, quality-control product reagent, treatment fluid, extract liquor, cleaning solution, eluent.Therapeutic Drug Monitoring kit of the invention, blood sample only need centrifugal treating, and it is small to repeat detection variability, Stability and veracity is high, testing cost is low, and every methodology index can meet the needs of Oxcarbazepine and its metabolite Therapeutic Drug Monitoring in blood, easy to spread.
Description
Technical field
The present invention relates to medical detection fields, more particularly to one kind to be based on multidimensional on-line solid phase extraction liquid-phase chromatographic analysis
Oxcarbazepine and its metabolite Therapeutic Drug Monitoring kit in the blood of technological development, more specifically using online solid
Mutually extraction and multidimensional liquid-phase chromatographic analysis technology carry out accurate quantitative analysis to Oxcarbazepine in blood and its metabolite drug concentration
The method of monitoring.
Background technique
The anticonvulsant action of Oxcarbazepine and its metabolite is mainly the Voltage-gated Sodium Channels for having blocked brain,
To block the propagation of the epilepsy electrical activity of epileptogenic focus.The effective blood drug concentration of Oxcarbazepine and its metabolite is 10-35mg/
L, as blood concentration > 35mg/L, toxic side effect enhancing.Adverse reaction is common out of strength, dizzy, headache etc., accidental stomach and intestine function
Energy obstacle, flush, blood count decline etc..Since Oxcarbazepine and its metabolite therapeutic window are relatively narrow, it is metabolized in vivo
There are biggish individual differences for process, so being adjustment dosage to the detection of its blood drug concentration, reduce adverse reaction
Important references are of great significance in clinical application.Oxcarbazepine and its metabolite therapeutic agent detect common at present
Method has: ultraviolet spectrophotometry, high performance liquid chromatography, Liquid Chromatography-Mass Spectrometry, surpasses and faces high performance thin layer chromatography
Boundary's chromatograph-mass spectrometer coupling method etc..In numerous methods, liquid chromatography is measure Oxcarbazepine and its metabolite most quasi-
True method.Previous methods are there are complex pretreatment, qualitative, quantitative is not accurate enough, at high cost, analysis time is long or to experiment people
The problems such as member's technical requirements are high.
Summary of the invention
An object of the present invention is in view of the deficiencies of the prior art, to provide a kind of based on multidimensional on-line solid phase extraction liquid phase
Oxcarbazepine and its metabolite Therapeutic Drug Monitoring kit in the blood of chromatographic technique exploitation, it is difficult to understand in blood to meet
The needs of oxcarbazepine and its metabolite Therapeutic Drug Monitoring.
It is a further object of the present invention to provide utilize kit monitoring Oxcarbazepine and its metabolite blood Chinese medicine
The method of object concentration.
The present invention is that technical solution used by solving its technical problem is:
Oxcarbazepine and its metabolite Therapeutic Drug Monitoring kit in a kind of blood, it is characterised in that: the reagent
Box includes calibration object reagent, quality-control product reagent, treatment fluid, extract liquor, cleaning solution, eluent.
Further, the calibration object reagent is containing Oxcarbazepine and its metabolite freeze-dried powder, stabilizer and plastotype agent
Animal blood serum, the concentration range of the Oxcarbazepine and its metabolite freeze-dried powder in animal blood serum be 1.5~55mg/L,
The concentration of the stabilizer is 10~30g/L, and the concentration of the plastotype agent is 10~30g/L；
Further, the quality-control product reagent is containing Oxcarbazepine and its metabolite freeze-dried powder, stabilizer and plastotype agent
Animal blood serum, the concentration range of the Oxcarbazepine and its metabolite freeze-dried powder in animal blood serum be 1.5~55mg/L,
The concentration of the stabilizer is 10~30g/L, and the concentration of the plastotype agent is 10~30g/L；
Preferably, the concentration of the stabilizer is 15~25g/L, and the concentration of the plastotype agent is 15~25g/L；
Further, the sample treatment solution is one or more of acetate buffer solution, acetonitrile and methanol
Mixture aqueous solution, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution.The methanol contains
Amount is 5%~15%, and the content of the acetonitrile is 5%~15%.
Further, the extract liquor includes extract liquor H1 and extract liquor H2；
Further, the extract liquor H1 is one or more of acetate buffer solution, acetonitrile and methanol
The aqueous solution of mixture, the acetate buffer solution content are 0.1 ‰~0.3 ‰, the content of the methanol is 3%~
10%, the content of the acetonitrile is 2%~8%.
Further, the extract liquor H2 is one or more of acetate buffer solution, acetonitrile and methanol
The aqueous solution of mixture, the content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution.The methanol contains
Amount is 30%~50%, and the content of the acetonitrile is 40%~70%.
Further, the cleaning solution is the aqueous solution of methanol or acetonitrile or two kinds of mixtures, the content of the methanol
It is 0%~40%, the content of the isopropanol is 0%~20%, and the content of the acetonitrile is 0%~50%.
Further, the eluent includes eluent A, eluent B and eluent C；
Further, the eluent A is the mixed of one or more of acetate buffer solution, acetonitrile and methanol
The aqueous solution of object is closed, the content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution, the content of the methanol
It is 0%~15%, the content of the acetonitrile is 70%~90%；
Further, the mixing of one or more of the eluent B acetate buffer solution, acetonitrile and methanol
The aqueous solution of object, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution, and the content of the methanol is 0%
~10%, the content of the acetonitrile is 5%~15%；The pH of the eluent B is 3~5；
Further, the mixing of one or more of the eluent C acetate buffer solution, acetonitrile and methanol
The aqueous solution of object, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution, and the content of the methanol is 0%
~10%, the content of the acetonitrile is 5%~15%；The pH of the eluent B is 6~8.
The acetate buffer solution includes the mixture of one or two of acetic acid, ammonium acetate, ammonium hydroxide or more.
Further, the stabilizer is bovine serum albumin(BSA) (BSA)；The plastotype agent mannitol and sucrose are a kind of
Or two kinds of mixture, the ratio of the mixture of the mannitol and sucrose is 1:2~5.
Further, the detection method of the kit includes the following steps: that blood sample takes supernatant after being centrifuged
Sample introduction, compensation is combined before and after carrying out in-line purification, enrichment, desorption and column by on-line solid phase extraction column, then passes through Vavle switching side
Target analytes in blood sample are sent into analytical column and are separated by formula, finally by UV detector or diode array
The analysis detections such as detector or mass detector, are calculated using calibration curve method, and drug is dense in final acquisition blood sample
Angle value.
Calculation formula is as follows: linear regression equation: y=ax+b, and wherein a is slope, and b is intercept, and y is actual measurement peak face
Product, x are mark concentration, and sample results calculate: the Oxcarbazepine of sample and its metabolite peak area are substituted into standard curve side
Journey calculates Oxcarbazepine and its Metabolites Concentration in sample；
Specific step is as follows:
(1) 1~4mL of sample to be tested is taken, 10min is centrifuged in the case where centrifugal speed is 3000~5000rpm, supernatant is taken to obtain
Serum or blood plasma；
(2) above-mentioned serum or blood plasma are taken, 1.0ml is pipetted and is added in sample bottle, be put into autosampler sample introduction 100ul into
Row liquid chromatogram quantitative detection；
Chromatographic condition: extraction column: SLCZ column (30 × 4.6mm, 10 μm of partial sizes)；Analytical column: C18 column (250 × 4.6mm, 5 μ
M partial size)；Mobile phase: extract liquor H1, extract liquor H2, eluent A, eluent B and eluent C；Column temperature: 35 DEG C；Sample volume: 100
μL；Wavelength: 239nm.
(3) drug concentration in sample is calculated according to above-mentioned formula.
The present invention has the advantages that
1, using multidimensional on-line solid phase extraction liquid-phase chromatographic analysis technology to Oxcarbazepine in blood and its metabolite
Drug concentration carries out accurate quantitative analysis detection, and testing result is Oxcarbazepine and its metabolite proto-drug concentration, and energy is more acurrate
The relationship illustrated before drug concentration-effect treatment-adverse reaction three；
2, blood sample is reduced brought by pre-treatment merely through centrifugal treating using blood plasma or serum direct injected
Error and personnel's operating error improve the accuracy, repeatability and the rate of recovery of quantitative result, greatly shorten detection time, make
Detection process is easy quickly, and experimental cost reduces, and more conducively detects in clinical treatment to the drug concentration of patient's body.
3, kit provided by the invention is commented by the drug concentration of Oxcarbazepine and its metabolite in detection blood
Estimate the clinical drug effect of Oxcarbazepine and its metabolite.I.e. the present invention also provides the kits in assessment anti-fungal infection medicine
Application in object clinical efficacy.
Detailed description of the invention
Fig. 1 is Oxcarbazepine and its metabolite chromatogram in Quality Control sample in embodiment；
Fig. 2 is Oxcarbazepine representative standard curve figure in embodiment
Fig. 3 is Oxcarbazepine metabolite representative standard curve figure in embodiment；
Fig. 4 is Oxcarbazepine and its metabolite chromatogram in serum sample in embodiment.
Specific embodiment
In order to be easy to understand the technical means, the creative features, the aims and the efficiencies achieved by the present invention, tie below
Diagram and specific embodiment are closed, the present invention is further explained.
One, the preparation of Oxcarbazepine and its metabolite Therapeutic Drug Monitoring kit:
Standard curve reagent: wherein Oxcarbazepine and its metabolite are with the animal blood containing 2% stabilizer and 2% moulding agent
It is configured to a series of concentration, respectively 1.5mg/L, 3.0mg/L, 6.0mg/L, 14.0mg/L, 27.0mg/L, 55.0mg/L clearly,
Every bottle of packing 1.0ml.The above component is lyophilized to be saved in measurement bottom of bottle.Quality-control product reagent: wherein Oxcarbazepine and its metabolism produce
Object is configured to high, normal, basic three concentration with the animal blood serum containing 2% stabilizer and 2% moulding agent, respectively 5.0mg/L,
25.0mg/L, 45.0mg/L, every bottle of packing 1.0ml.The above component is lyophilized to be saved in measurement bottom of bottle.
Sample treatment solution: precision weighs 0.12g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 700ml to dissolve, adds
Acetic acid adjusts pH value 5.0, then plus acetonitrile 100ml and methanol 100ml, then plus distilled water is diluted to scale to get dispensing, patch
Label label, completes operation.
Extract liquor H1: precision weighs 0.12g ammonium acetate, sets in 1000mL volumetric flask, and distilled water 700ml is added to dissolve, then plus
Acetonitrile 50mL, then plus distilled water is diluted to scale to get packing, labeling label completes operation.
Extract liquor H2: precision weighs 0.12g ammonium acetate, sets in 1000mL volumetric flask, and distilled water 100ml is added to dissolve, then plus
Acetonitrile 800ml, then plus distilled water is diluted to scale to get packing, labeling label completes operation.
Cleaning solution: precision weighs methanol 200ml and acetonitrile 350ml, sets in 1000mL volumetric flask, and distilled water is added to be diluted to quarter
Degree is to get packing, labeling label completes operation.
Eluent A: precision weighs 0.12g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 250ml to dissolve, then plus second
Nitrile 700mL, then plus distilled water is diluted to scale to get packing, labeling label completes operation.
Eluent B: precision weighs 0.12g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 700ml to dissolve, adds acetic acid
PH value is adjusted to 3.5, then plus acetonitrile 100ml, then plus distilled water is diluted to scale to get packing, labeling label completes behaviour
Make.
Eluent C: precision weighs 0.12g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 700ml to dissolve, adds 10%
Ammonium hydroxide adjusts pH value to 7.0, then plus acetonitrile 50ml, then plus distilled water is diluted to scale to get packing, labeling label is completed
Operation.
Two, the detecting step using above-mentioned monitoring reagent box is as follows:
1, it is applicable in instrument
Fully automatic therapy drug test analysis system (SLC), high performance liquid chromatograph (HPLC), liquid chromatography-tandem matter
Spectrometer (LC-MS/MS).
2, sample requirement
Venous whole sample is acquired, is placed in anticoagulant tube, 2~8 DEG C of refrigerators is placed in immediately and seals standby survey up for safekeeping.
3, the method for inspection
Sample pretreatment:
Sample treatment solution is taken, 0.5ml is quantitatively pipetted and is added in sample reagent bottle；Sample to be tested at least 4mL is taken, is being centrifuged
Speed is to be centrifuged 10min under 4000rpm, pipettes supernatant 1.0ml and is added in sample bottle, and vortex mixes, and is put into autosampler
Middle sample introduction, and carry out liquid chromatogram quantitative detection；
Chromatographic condition:
On-line extraction column: SLCZ column (30 × 4.6mm, 10 μm of partial sizes)；
On-line analysis column: C18 column (250 × 4.6mm, 5 μm of partial sizes)；
Mobile phase: extract liquor H1, extract liquor H2, eluent A, eluent B and eluent C；
Column temperature: 35 DEG C；Sample volume: 100 μ L；Wavelength: 239nm.
1 condition of gradient elution of table
Measuring method:
After taking calibration object, quality-control product, sample to be tested to carry out Sample pretreatment, 100 μ L of supernatant sample introduction is taken to carry out chromatography fixed
Amount analysis, records chromatographic peak area.
Quality Control requirement:
Every 1 analysis 1 standard curve of this retinue of lot sample (6 each 1 of various concentration value calibration product samples) and 6 Quality Control samples
This (each 2 of high, medium and low concentration).Quality-control product sample measures result error should be less than 10%, at most allow 1/3 quality-control product sample
This result is more than above-mentioned limit, but there can be no in same concentration quality-control product sample.As quality-control product sample measures result is not inconsistent
Above-mentioned requirements are closed, then the analysis batch sample tests cancel, and detect again.
4, result calculates
As shown in Figs 1-4,
Specification Curve of Increasing:
With the calibration object concentration (1.5,3.0,6.0,14.0,27.0,55.0mg/L) of 6 different mark concentration for abscissa
(x), using the actual measurement peak area of 6 calibration object samples as ordinate (y), standard curve is drawn.
The fitting of calibration curve equation:
With the actual measurement peak area (y) of 6 calibration object samples to mark concentration (x) using weighting (1/x2) least square method into
Row linear regression.Oxcarbazepine linear regression equation: Y=0.7761X-0.3353, wherein 0.7761 is slope ,-
0.3353 is intercept, and calculates related coefficient (r), and r should be not less than 0.9900.R is 0.9999；The fitting of Oxcarbazepine metabolite
Equation of linear regression: Y=0.3699X+0.0420, wherein 0.3699 is slope, 0.0420 is intercept, and calculates related coefficient
(r), r should be not less than 0.9900.R is 0.9999.
The calculating of the rate of recovery:
The Oxcarbazepine of quality-control product sample measures and its metabolite peak area are substituted into above-mentioned standard curvilinear equation, calculated
The Oxcarbazepine and its metabolite of quality-control product sample measure concentration.The calculation formula of the quality-control product sample rate of recovery are as follows: the rate of recovery
(%)=measurement concentration/mark concentration × 100, the rate of recovery (%) should be in 100 ± 15% ranges.The Oxcarbazepine rate of recovery:
92.7%；The Oxcarbazepine metabolite rate of recovery: 95.3%.Sample results calculate:
The Oxcarbazepine of sample and its metabolite peak area are substituted into calibration curve equation, calculate the Oxcarbazepine of sample
And its metabolite drug concentration.Oxcarbazepine is calculated and its metabolite drug concentration is 2.94ug/mL；
3.51ug/mL。
It summarizes, under the process conditions, the calibration curve coefficient correlation and quality-control product of Oxcarbazepine and its metabolite are returned
Yield meets regulation, it is ensured that the accuracy of this method institute sample result.
The basic principles, main features and advantages of the present invention have been shown and described above.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, various changes and improvements may be made to the invention without departing from the spirit and scope of the present invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent defines.
Claims (10)
1. Oxcarbazepine monitor drug concentration kit in a kind of blood, it is characterised in that: the kit includes calibration object examination
Agent, quality-control product reagent, treatment fluid, extract liquor, cleaning solution, eluent.
2. kit according to claim 1, it is characterised in that: the calibration object reagent is containing Oxcarbazepine and its metabolism
The animal blood serum of product freeze-dried powder, stabilizer and plastotype agent, the Oxcarbazepine and its metabolite freeze-dried powder are in animal blood serum
In concentration range be 1.5~55mg/L, concentration gradient be 1.5~55mg/L；The concentration of the stabilizer is 10~30g/L,
The concentration of the plastotype agent is 10~30g/L；
The quality-control product reagent is the animal blood serum containing Oxcarbazepine and its metabolite freeze-dried powder, stabilizer and plastotype agent, institute
Stating the concentration range of Oxcarbazepine and its metabolite freeze-dried powder in animal blood serum is 1.5~55mg/L, the stabilizer
Concentration is 10~30g/L, and the concentration of the plastotype agent is 10~30g/L.
3. kit according to claim 1, it is characterised in that: the concentration of the stabilizer is 15~25g/L, the modeling
The concentration of type agent is 15~25g/L.
4. kit according to claim 1, it is characterised in that: the sample treatment solution is acetate buffer solution, second
The aqueous solution of the mixture of one or more of nitrile and methanol, the content of ammonium acetate is in the acetate buffer solution
0.1 ‰~0.3 ‰, the content of the methanol is 5%~15%, and the content of the acetonitrile is 5%~15%.
5. kit according to claim 1, it is characterised in that: the extract liquor includes extract liquor H1 and extract liquor H2；
The extract liquor H1 is the water-soluble of the mixture of one or more of acetate buffer solution, acetonitrile and methanol
Liquid, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution, and the content of the methanol is 3%~10%,
The content of the acetonitrile is 2%~8%.
The extract liquor H2 is the water-soluble of the mixture of one or more of acetate buffer solution, acetonitrile and methanol
Liquid, the content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution, the content of the methanol is 30%~
50%, the content of the acetonitrile is 40%~70%.
6. kit according to claim 1, it is characterised in that: the cleaning solution is methanol or acetonitrile or two kinds of mixing
The aqueous solution of object.
7. kit according to claim 1, it is characterised in that: the eluent include eluent A, eluent B and
Eluent C；
The eluent A is the aqueous solution of the mixture of one or more of acetate buffer solution, acetonitrile and methanol,
The content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution, and the content of the methanol is 0%~15%, institute
The content for stating acetonitrile is 70%~90%；
The aqueous solution of the mixture of one or more of the eluent B acetate buffer solution, acetonitrile and methanol, institute
The content for stating ammonium acetate in acetate buffer solution is 0.1 ‰~0.3 ‰, and the content of the methanol is 0%~10%, the second
The content of nitrile is 5%~15%；The pH of the eluent B is 3~5；
The aqueous solution of the mixture of one or more of the eluent C acetate buffer solution, acetonitrile and methanol, institute
The content for stating ammonium acetate in acetate buffer solution is 0.1 ‰~0.3 ‰, and the content of the methanol is 0%~10%, the second
The content of nitrile is 5%~15%；The pH of the eluent B is 6~8.
8. according to kit described in claim 4~7 any one, it is characterised in that: the acetate buffer solution includes vinegar
The mixture of the one or two of acid, ammonium acetate, ammonium hydroxide or more.
9. kit according to claim 2 or 3, it is characterised in that: the stabilizer is bovine serum albumin(BSA)
(BSA)；The ratio of the mixture of the mixture of the plastotype agent mannitol and sucrose one or two, the mannitol and sucrose
Example is 1:2~5.
10. a kind of detection method of kit described in claim 1, include the following steps: that blood sample takes after being centrifuged on
Clear liquid sample introduction, compensation is combined before and after carrying out in-line purification, enrichment, desorption and column by on-line solid phase extraction column, then is cut by valve
Changing mode will separate in target analytes feeding analytical column in blood sample, finally by UV detector or diode
The analysis detections such as array detector or mass detector, are calculated using calibration curve method, final to obtain blood sample Chinese medicine
Object concentration value；
Calculation formula is as follows: linear regression equation: y=ax+b, and wherein a is slope, and b is intercept, and y is actual measurement peak area, x
To indicate concentration, sample results are calculated: the Oxcarbazepine of sample and its metabolite peak area are substituted into calibration curve equation, meter
Calculate the Oxcarbazepine and its Metabolites Concentration in sample；
Specific step is as follows:
(1) 1~4mL of sample to be tested is taken, 10min is centrifuged in the case where centrifugal speed is 3000~5000rpm, supernatant is taken to obtain serum
Or blood plasma；
(2) above-mentioned serum or blood plasma are taken, 1.0ml is pipetted and is added in sample bottle, sample introduction 100ul in autosampler is put into and carries out liquid
The detection of phase chromatogram quantification；
(3) drug concentration in sample is calculated according to above-mentioned formula.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910671617.9A CN110361485A (en) | 2019-07-24 | 2019-07-24 | Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910671617.9A CN110361485A (en) | 2019-07-24 | 2019-07-24 | Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110361485A true CN110361485A (en) | 2019-10-22 |
Family
ID=68220937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910671617.9A Withdrawn CN110361485A (en) | 2019-07-24 | 2019-07-24 | Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110361485A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110763800A (en) * | 2019-11-12 | 2020-02-07 | 北京和合医学诊断技术股份有限公司 | Method for detecting oxcarbazepine and 10, 11-dihydro-10-hydroxycarbazepine in blood |
| CN114671809A (en) * | 2020-12-25 | 2022-06-28 | 苏州博源医疗科技有限公司 | Oxcarbazepine derivative, immunogen, anti-oxcarbazepine specific antibody, preparation method and application thereof |
-
2019
- 2019-07-24 CN CN201910671617.9A patent/CN110361485A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110763800A (en) * | 2019-11-12 | 2020-02-07 | 北京和合医学诊断技术股份有限公司 | Method for detecting oxcarbazepine and 10, 11-dihydro-10-hydroxycarbazepine in blood |
| CN114671809A (en) * | 2020-12-25 | 2022-06-28 | 苏州博源医疗科技有限公司 | Oxcarbazepine derivative, immunogen, anti-oxcarbazepine specific antibody, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111175394B (en) | Method for detecting plasma catecholamine and metabolite thereof by liquid chromatography-tandem mass spectrometry | |
| Liu et al. | Global characterization of neutral saccharides in crude and processed Radix Rehmanniae by hydrophilic interaction liquid chromatography tandem electrospray ionization time-of-flight mass spectrometry | |
| Keevil | Does the presence of 3-epi-25OHD3 affect the routine measurement of vitamin D using liquid chromatography tandem mass spectrometry? | |
| Riggin et al. | Liquid chromatographic method for monitoring therapeutic concentrations of L-dopa and dopamine in serum. | |
| Alam et al. | Measurement of homocysteine: a historical perspective | |
| CN109030658B (en) | Method for detecting fructo-oligosaccharide and raffinose in infant milk powder | |
| CN102141552A (en) | High-sensitivity whole blood tacrolimus quantitative assay kit and preparation method thereof | |
| CN110361485A (en) | Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood | |
| Breaud et al. | A rapid and reliable method for the quantitation of tricyclic antidepressants in serum using HPLC-MS/MS | |
| CN109633181A (en) | The detection kit of metanephrine and normetanephrine in a kind of blood plasma | |
| CN106959345A (en) | A kind of full Isotopic Internal Standard mass spectrum quantitative approach of neurotransmitter metabolite | |
| DeFelice et al. | Rapid LC-MS/MS quantification of cancer related acetylated polyamines in human biofluids | |
| CN111458417B (en) | Method and kit for combined detection of multiple antibiotics in sample to be detected | |
| CN110361488A (en) | Lamotrigine monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361482A (en) | Linezolid monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361481A (en) | Vancomycin monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361484A (en) | Amiodarone monitor drug concentration kit and its detection method in a kind of blood | |
| CN110045037A (en) | A kind of kit and detection method detecting nilotinib drug concentration in dry blood cake | |
| CN105891368A (en) | Method for detecting acetyl choline content in peripheral blood mononuclear cells | |
| CN110361489A (en) | Amitriptyline monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361486A (en) | Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood | |
| CN113125600B (en) | Method for simultaneously determining concentration of 3 vitamin B12 in serum | |
| CN114264765B (en) | Analytical method for determining related substances in glimepiride intermediate by utilizing HPLC | |
| Nishida et al. | Miniaturized sample preparation method for determination of amphetamines in urine | |
| CN114397379A (en) | Method for determining concentration of ornidazole in blood plasma by liquid chromatography-mass spectrometry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191022 |